Phase III FIRE-3 trial data show most patients with wild-type RAS metastatic colorectal cancer benefit from first-line FOLFIRI plus cetuximab treatment

Findings from a preplanned analysis by mutational status done on data from the FIRE-3 trial, that expanded KRAS testing as a predictive factor of resistance to more rare NRAS gene and BRAF, confirmed previously reported results that first line treatment with FOLFIRI plus the anti-EGFR agent cetuximab achieve benefit in term of overall response rate and overall survival in most patients with KRAS wild type (exon 2) metastatic colorectal cancer, but the benefit encompass also those with wild type KRAS exon 3/4 and wild type NRAS exon 2/3/4. Read more here.